Benzinga | Jan 19, 2021 06:32AM EST

Morgan Stanley Downgrades Editas Medicine to Underweight, Lowers Price Target to $45

Morgan Stanley analyst Matthew Harrison downgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Underweight and lowers the price target from $64 to $45.